Jerry Cohen, DO
Geriatric Medicine · Narberth, PANPI 1629015680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 102 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$235
- Otsuka America Pharmaceutical, Inc.$140
- Astellas Pharma US Inc$139
- Sun Pharmaceutical Industries Inc.$132
- Amarin Pharma, Inc.$129
- Acadia Pharmaceuticals Inc$97
- plus $971 from 26 others
What the payments were for
- Food & beverage$1,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 13 | $235 |
| Otsuka America Pharmaceutical, Inc. | 7 | $140 |
| Astellas Pharma US Inc | 7 | $139 |
| Sun Pharmaceutical Industries Inc. | 8 | $132 |
| Amarin Pharma, Inc. | 8 | $129 |
| Acadia Pharmaceuticals Inc | 6 | $97 |
| Novartis | 5 | $91 |
| Johnson & Johnson | 4 | $88 |
| Sunovion Pharmaceuticals Inc. | 6 | $76 |
| AstraZeneca | 4 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Lilly USA, LLC | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $50 |
| SK Life Science, Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| UCB, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $25 |
| Biogen | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Urovant Sciences Inc | 1 | $19 |
| Merck | 1 | $17 |
| Vivus LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Aprecia Pharmaceuticals, LLC | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$1,844 in reported general payments places this provider in the 85th percentile of 217 geriatric medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 911 | $286,740 |
| SantylCollagenase Clostridium Hist. | 39 | $266,924 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 45 | $178,576 |
| TrulicityDulaglutide | 135 | $71,902 |
| Abilify MaintenaAripiprazole | 20 | $60,189 |
| XareltoRivaroxaban | 152 | $53,404 |
| FarxigaDapagliflozin Propanediol | 119 | $44,581 |
| NuedextaDextromethorphan Hbr/Quinidine | 48 | $38,975 |
| JanuviaSitagliptin Phosphate | 92 | $33,111 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $27,037 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $26,361 |
| Atorvastatin Calcium | 1,465 | $24,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $24,142 |
| JardianceEmpagliflozin | 58 | $22,152 |
| Divalproex Sodium | 502 | $19,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $55 | $71,902135 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat | $37 | $63,762150 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $140 | $60,18920 claims |
| AstraZenecaFarxiga, Lokelma | $75 | $58,723139 claims |
| Johnson & JohnsonXarelto | $88 | $53,404152 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $235 | $38,97548 claims |
| MerckJanuvia | $17 | $33,11192 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $10,94130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 217 geriatric medicine providers in Pennsylvania.
Other geriatric medicine in Narberth
- Steven LewisNarberth$3K
- Richard StefanacciPhiladelphia$146K
- James LinErie$73K
- Adele TowersPittsburgh$29K
- Michele ZaworaPhiladelphia$21K
- Daniel HaimowitzLevittown$15K
- Robert PearlsteinPlymouth Meeting$15K
- Seth CarterErie$14K
- Moushumi KunduHanover$12K
- Jason KarlawishPhiladelphia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.